CureVac’s Market Exit: A New Chapter Begins Under BioNTech

CureVac NL0015436031

The independent story of CureVac's publicly traded shares has concluded. In a landmark consolidation within the European biotechnology sector, BioNTech finalized its acquisition of the Tübingen-based mRNA specialist in early 2026. This move effectively removed one of Germany's most prominent biotech names from the stock exchange, integrating a former pioneer in German vaccine development entirely into the Mainz-based corporation.

Formal completion of the deal occurred on January 6, 2026. Following a public exchange offer and subsequent corporate restructuring, BioNTech assumed ownership of all CureVac business operations. The original entity, CureVac N.V., was succeeded by CureVac Merger B.V., and all remaining publicly held shares were delisted and canceled.

• Delisting Date: CureVac equity ceased trading in January 2026.
• New Ownership: BioNTech emerged as the sole proprietor.
• Ticker Symbol: The CVAC ticker was removed from the Nasdaq.

Shareholders who participated in the exchange offer received BioNTech American Depositary Shares (ADSs) based on a predetermined conversion ratio. Consequently, their investment was effectively transitioned into a stake in the acquiring company.

Creating a European mRNA Powerhouse

This acquisition represents a significant strategic consolidation. BioNTech has secured rights to an extensive patent portfolio, including intellectual property that was previously the subject of legal disputes between the two firms. For the broader biotech industry, the merger signals a reduction in competitors but a concentration of research and development resources.

BioNTech now incorporates CureVac's Tübingen research facilities and its clinical pipeline, which features candidates targeting cancer vaccines and infectious diseases. Market observers have interpreted this strategic maneuver as a move to bolster BioNTech's competitive position against global rivals in the mRNA technology arena.

Investor Focus Shifts to BioNTech's Integration

With CureVac no longer existing as a standalone investment, market attention turns squarely to BioNTech (Nasdaq: BNTX). The critical factor for investors will be the efficiency of the integration process, particularly concerning the operational assimilation of CureVac's Tübingen production capacities. Furthermore, BioNTech's future quarterly financial reports are expected to reflect consolidated results, incorporating operational costs and the anticipated synergies stemming from the CureVac acquisition.

@ boerse-global.de | NL0015436031 CUREVAC’S